^
    Back
    Association details:
    Biomarker:NCAM1 expression
    Cancer:Solid Tumor
    Drug:lorvotuzumab mertansine (IMGN901) (Microtubule inhibitor, CD56-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors

    Excerpt:
    ...- Diagnoses other than SCLC must have confirmation of tumor CD56 expression before study entry...
    Trial ID:
    NCT00346385
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma

    Excerpt:
    ...miscellaneous CD56-expressing tumors:...
    Trial ID:
    NCT02452554
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Invest New Drugs
    Title:

    Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors

    Excerpt:
    This phase 1 study investigated the safety, tolerability, pharmacokinetics, and preliminary activity of IMGN901 in patients with CD56-expressing solid tumors….Responses included 1 complete response (CR), 1 clinical CR, and 1 unconfirmed partial response (PR) in MCC; and 1 unconfirmed PR in SCLC. Stable disease was seen for 25 % of all evaluable patients who received doses ≥60 mg/m2....Objective responses were observed in patients with advanced CD56+ cancers.
    DOI:
    https://doi.org/10.1007/s10637-016-0336-9